The effectiveness of cyproheptadine in the treatment of acute akathisia caused by neuroleptics

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20191218045795N7

Enrollment

Registered

2023-02-25

Start date

2023-03-21

Completion date

Unknown

Last updated

2023-03-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Akathisia. Drug induced akathisia

Interventions

Intervention 1: Intervention group: The intervention in this study is Cyproheptadine. First, Cyproheptadine powder (manufactured by Tekaje-Iran ) which is prepared by a pharmacologist, is poured into

Eligibility

Sex/Gender

All

Age

20 Years to 65 Years

Inclusion criteria

Inclusion criteria: Get antipsychotic A minimum score of 2 on the akathisia scale BARS

Exclusion criteria

Exclusion criteria: Receiving beta blocker, mianserin, cyproheptadine, vitamin B6 Suiccidal thoughtsevere Severe akathisia (score higher than 5 in BARS)

Design outcomes

Primary

Measure	Time frame
BARS akathisia score. Timepoint: At the beginning of the study (before the start of the intervention) and 5 days after the start of cyproheptadine. Method of measurement: BARS akathisia questionaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNarges Shamsalizadeh

Sanandaj University of Medical Sciences

nshamsalizadeh@yahoo.com+98 87 3366 4957

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026